Company: CYTK
Filing Date: 2025-02-27
Form Type: S-3ASR
Source: 0001193125-25-039426
Chunk: 51

Company: CYTOKINETICS INC
Filing Date: 2025-02-27
Form: S-3ASR
Chunk 51
---
 public offering price per share                                                       
 Net tangible book value per share of as December 31, 2024                                     |     |   | (1.15 | ) |     |   | 46.86 |
|:----------------------------------------------------------------------------------------------|:----|:--|------:|:--|:----|:--|------:|
| Increase in net tangible book value per share attributable to this offering                   |     | $ |  3.86 |   |     |   |       |
| As adjusted net tangible book value per share as of December 31, 2024, after giving effect to 
 this offering                                                                                 |     |   |       |   |     |   |  2.71 |
| Dilution per share to new investors purchasing our common stock in this offering              |     |   |       |   |     | $ | 44.15 |

The table above assumes for illustrative purposes that an aggregate of 10,670,081 shares of our common stock are sold during the term of the Sales Agreement with Jefferies at a price of $46.86 per share, the last reported sale price of our common stock on The Nasdaq Global Select Market on February 26, 2025, for aggregate gross proceeds of $500.0 million. The shares subject to the Sales Agreement with Jefferies are being sold from time to time at various prices. An increase of $3.00 per share in the price at which the shares are sold from the assumed offering price of $46.86 per share shown in the table above, assuming all of our common stock in the aggregate amount of $500.0 million during the term of the Sales Agreement with Jefferies is sold at that price, would increase our adjusted net tangible book value per share after the offering to $2.72 per share and would increase the dilution in net tangible book value per share to new investors in this offering to $3.87 per share, after deducting commissions and estimated offering expenses payable by us. A decrease of $3.00 per share in the price at which the shares are sold from the assumed offering price of $46.86 per share shown in the table above, assuming all of our common stock in the aggregate amount of $500.0 million during the term of the Sales Agreement with Jefferies is sold at that price, would decrease our adjusted net tangible book value per share after the offering to $2.69 per share and would decrease the dilution in